person · Reporting owner
Flowers Cynthia Louise
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,446 |
Reported balance
After 2026-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 30,456 · Balance 95,446 F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2: Includes 30,456 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.
F2: Includes 30,456 unvested restricted stock units.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
G1 Therapeutics, Inc.
Report date September 18, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-18 · Disposition to issuer · Disposed 20,000 · Balance 15,889 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 2 · 2024-09-18 · Other · Disposed 15,889 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2032-06-23 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").
F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Kadmon Holdings, Inc.
Report date November 08, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-11-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-11-08 · Gift · Disposed 20,150 · Balance 10,850 Row 2 · 2021-11-09 · Disposition to issuer · Disposed 10,850 · Balance 0 F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2029-01-22 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 64,935 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-05-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2030-05-13 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 85,034 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-09 · Disposition to issuer · Disposed 96,975 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:04 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 30,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001741455-26-000003 · wk-form4_1768338264.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,446 F1 · shares: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2 · balance_after: Includes 30,456 unvested restricted stock units. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:03 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 15,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001741455-25-000002 · wk-form4_1736802222.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,990 F1 · shares: Represents 15,789 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2026. F2 · balance_after: Includes 15,789 unvested restricted stock units. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $5.30 | Not disclosed |
DisclosureSEC source: 0000950170-24-107798 · ownership.xml · derivative · entry 5 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2032-06-23 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.83 | Not disclosed |
DisclosureSEC source: 0000950170-24-107798 · ownership.xml · derivative · entry 4 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.99 | Not disclosed |
DisclosureSEC source: 0000950170-24-107798 · ownership.xml · derivative · entry 3 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | OtherCommon Stock | 15,889 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107798 · ownership.xml · nonDerivative · entry 2 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107798 · ownership.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,889 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · kind: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · price: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:39 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001562180-24-005079 · primarydocument.xml · derivative · entry 2 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:39 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005079 · primarydocument.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,889 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 15,889 shares of common stock; (ii) 10,000 RSUs from award granted on June 15, 2023; and (iii) 10,000 RSUs from award granted on June 13, 2024. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:05 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 19,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001741455-24-000002 · wk-form4_1705007128.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,201 F1 · shares: Represents 19,480 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2025. F2 · balance_after: Includes 19,480 unvested restricted stock units. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001562180-23-005271 · primarydocument.xml · derivative · entry 2 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:07 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005271 · primarydocument.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,889 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 5,889 shares of common stock; (ii) 10,000 RSUs from award granted on June 23, 2022; and (iii) 10,000 RSUs from award granted on June 15, 2023. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:15 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001741455-23-000002 · wf-form4_167347173416107.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,721 F1 · shares: Represents 20,000 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2024. F2 · balance_after: Includes 24,362 unvested restricted stock units. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 16:51 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001562180-22-005351 · primarydocument.xml · derivative · entry 2 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-23 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 16:51 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005351 · primarydocument.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,889 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock F3 · balance_after: Represents 5,889 shares of common stock and 10,000 restricted stock units Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:10 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001741455-22-000002 · wf-form4_164202181534309.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,847 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 103,165 unvested restricted stock units. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 96,975 | $5.92 Strike: $3.58 | $574,092.00 |
DisclosureSEC source: 0001104659-21-136411 · tm2131118-10_4seq1.xml · derivative · entry 6 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 96,975 shares Expires 2031-05-12 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 85,034 | $5.06 Strike: $4.44 | $430,272.04 |
DisclosureSEC source: 0001104659-21-136411 · tm2131118-10_4seq1.xml · derivative · entry 5 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 85,034 shares Expires 2030-05-13 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $7.21 Strike: $2.29 | $721,000.00 |
DisclosureSEC source: 0001104659-21-136411 · tm2131118-10_4seq1.xml · derivative · entry 4 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2029-05-15 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 64,935 | $7.23 Strike: $2.27 | $469,480.05 |
DisclosureSEC source: 0001104659-21-136411 · tm2131118-10_4seq1.xml · derivative · entry 3 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 64,935 shares Expires 2029-01-22 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerCommon Stock | 10,850 | $9.50 | $103,075.00 |
DisclosureSEC source: 0001104659-21-136411 · tm2131118-10_4seq1.xml · nonDerivative · entry 2 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GiftCommon Stock | 20,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-136411 · tm2131118-10_4seq1.xml · nonDerivative · entry 1 Flowers Cynthia Louise · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 19,620 | $0.00 Strike: $21.97 | $0.00 |
DisclosureSEC source: 0001562180-21-004397 · primarydocument.xml · derivative · entry 2 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,620 Underlying: Common Stock · 19,620 shares Expires 2031-06-17 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:25 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 4,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004397 · primarydocument.xml · nonDerivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,889 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock F3 · balance_after: Represents 1,500 shares of common stock and 4,389 restricted stock units Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:17 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 96,975 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001593968-21-001315 · primary_01.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,975 Underlying: Common stock · 96,975 shares Expires 2031-05-12 F1 · derivative.exercise_date: The stock option vests in full on the first anniversary of the grant date, or May 12, 2022 Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:20 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001741455-21-000003 · wf-form4_161049361662902.xml · nonDerivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,417 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 60,117 unvested restricted stock units. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 16:42 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.59 | $0.00 |
DisclosureSEC source: 0001209191-20-036308 · doc4.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 11, 2020, subject to the Reporting Person's continued service as a director. Read SEC document |
| May 13, 2020 Filed May 14, 2020 16:27 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 85,034 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001593968-20-001175 · primary_01.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,034 Underlying: Common stock, $0.001 par value · 85,034 shares Expires 2030-05-13 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 13, 2021. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 17:57 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | PurchaseCommon stock, par value $0.001 | 21,693 | $3.24 | $70,285.32 |
DisclosureSEC source: 0001593968-20-000754 · primary_01.xml · nonDerivative · entry 2 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 17:57 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | PurchaseCommon stock, par value $0.001 | 9,307 | $3.24 | $30,108.15 |
DisclosureSEC source: 0001593968-20-000754 · primary_01.xml · nonDerivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307 Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 21:18 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 18,292 | $3.28 | $59,997.76 |
DisclosureSEC source: 0001741455-20-000002 · wf-form4_157903667938717.xml · nonDerivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,682 F1 · shares: Represents 18,292 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 13, 2021. F2 · balance_after: Includes 18,292 unvested restricted stock units. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-19-037144 · doc4.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 12, 2019, subject to the Reporting Person's continued service as a director. Read SEC document |
| May 15, 2019 Filed May 16, 2019 16:51 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 100,000 | $2.29 Strike: $2.29 | $229,000.00 |
DisclosureSEC source: 0001593968-19-001124 · primary_01.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,935 Underlying: Common stock, $0.001 par value · 100,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: The stock option becomes vested and exercisable on May 15, 2020. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 16:27 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantOption (right to buy) · Derivative | 64,935 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001593968-19-000195 · primary_01.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,935 Underlying: Common Stock, par value $0.001 · 64,935 shares Expires 2029-01-22 F1 · derivative.exercise_date: The option becomes vested and exercisable in three equal annual installments over 3 years from January 22, 2019, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:10 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 12,121 | $4.95 | $59,998.95 |
DisclosureSEC source: 0001741455-19-000003 · wf-form4_154767302188946.xml · nonDerivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,390 F1 · shares: Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020. F2 · balance_after: Includes 24,390 unvested restricted stock units. Read SEC document |
| December 26, 2018 Filed Dec 27, 2018 16:59 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 1,420 | $18.45 | $26,196.44 |
DisclosureSEC source: 0001562180-18-005114 · primarydocument.xml · nonDerivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 21:19 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units · Derivative | 12,269 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001741455-18-000014 · wf-form4_154171193038892.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,269 Underlying: Common Stock · 12,269 shares Expires 2028-11-07 F1 · security: Represents 12,269 shares of restricted stock units granted under the 2018 Equity Incentive Compensation Plan. The shares of restricted stock units will vest in annual installments over a three-year period with the initial vesting on November 7, 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 11:52 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $38.39 | $0.00 |
DisclosureSEC source: 0001209191-18-036861 · doc4.xml · derivative · entry 1 Schwalm Cynthia · CIK 0001741455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The shares underlying this option will vest in equal monthly installments over a period of three years, subject to the Reporting Person's continued service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.